- Clinical Trials
- April 2024
- 60 Pages
Global
From €1201EUR$1,250USD£1,027GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,161GBP
- Report
- January 2022
- 60 Pages
Global
From €3795EUR$3,950USD£3,245GBP
- Report
- January 2024
- 72 Pages
Global
From €3500EUR$3,902USD£3,097GBP
- Drug Pipelines
- June 2021
- 86 Pages
Global
From €1922EUR$2,000USD£1,643GBP
- Drug Pipelines
- August 2020
- 81 Pages
Global
From €1922EUR$2,000USD£1,643GBP
Coccidioidomycosis is an infectious disease caused by the fungus Coccidioides. Treatment of the disease is typically done with antifungal medications, such as fluconazole, itraconazole, and amphotericin B. These medications are used to treat both acute and chronic forms of the disease. The Coccidioidomycosis Drug market is composed of a variety of pharmaceutical companies that produce and distribute these medications.
The Coccidioidomycosis Drug market is highly competitive, with many companies offering different formulations of the same medications. Companies in the market include Pfizer, Merck, GlaxoSmithKline, Novartis, and Sanofi. These companies are all major players in the pharmaceutical industry, and they are all involved in the production and distribution of Coccidioidomycosis Drugs. Show Less Read more